Conference articles (International)

[16] Yonghyun Lee, Kohei Sugihara, Nobuhiko Kamada, and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” 2019 Biomedical Engineering Society Annual Meeting, Oct 16-19, 2019, Philadelphia, USA. (Oral Presentation)

[15] Alireza Hassani Najafabadi, D. Hendy, Yonghyun Lee, A. Munie, P. Duncker, N. Wilkinson, Anna Schwendenman, B.M. Segal, James Moon. “Myelin-based peptide-conjugated nanodiscs to promote immunological tolerance against multiple sclerosis/experimental autoimmune encephalomyelitis.” The 46th Annual Meeting & Exposition of the Controlled Release Society, Jul 21-24, 2019, Valencia, Spain. (Oral Presentation)

[14] Yonghyun Lee, Nobuhiko Kamada, Merritt G. Gilliland III, Sangyong Jon, and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” The 46th Annual Meeting & Exposition of the Controlled Release Society, Jul 21-24, 2019, Valencia, Spain. (Oral Presentation)

[13] Yonghyun Lee, Merritt G. Gillilland III, Nobuhiko Kamada, and James Moon. “Hyaluronic acid-bilirubin nanoparticles for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Cancer Hematopoiesis and Immunology Program, Rogel Cancer Center (CHI Seminar), University of Michigan, Mar 1, 2019, Ann Arbor, U.S.A. (Oral Presentation)

[12] Yonghyun Lee, Merritt G. Gillilland III, Nobuhiko Kamada, and James Moon. “Hyaluronic acid-bilirubin nanoparticles for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Pharmaceutical Sciences Seminar. College of Pharmacy, University of Michigan, Dec 5, 2018, Ann Arbor, U.S.A. (Oral Presentation)

[11] Yonghyun Lee, Merritt G. Gillilland III, Nobuhiko Kamada, and James Moon. “Novel nanoparticle system for treatment of acute colitis” Drug Carriers in Medicine and Biology Gordon Research Conference. Aug 12-17, 2018, West Dover, U.S.A. (Poster Presentation)

[10] Dong-eon Kim*, Yonghyun Lee*, Mingyo Kim, Soyoung Lee, Sangyong Jon, and Seung-Hyo Lee. “Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma” 5th Annual Meeting of the International-Cytokine-and-Interferon-Society. Oct 29-Nov 02, 2017. Kanazawa, Japan. (Poster Presentation)

[9] Yonghyun Lee, Soyoung Lee, and Sangyong Jon. “Biotin-conjugated bilirubin nanoparticles for tumor microenvironments-targeted cancer therapy.” The 44th Annual Meeting & Exposition of the Controlled Release Society, July 16-19, 2017, Boston, U.S.A. (Porster Presentation)

[8] Yonghyun Lee. “Development of new drug candidates using novel approaches” The 1st KAST-KSSEA Young Generation Scientist and Engineers Open Forum. Dec 7-12, 2016, Stockholm, Sweden. (Oral Presentation, Nobel Prize Award Week)

[7] Yonghyun Lee, Soyoung Lee, and Sangyong Jon. “Multi-stimuli-responsive bilirubin nanoparticles for anticancer therapy and anti-inflammatory therapy.” The 1^st International Society for Nanomedicine. Sep 28-30, 2016, Seoul, Korea. (Poster presentation, Best Poster Award, Silver Award)

[6] Hyungjun Kim, Yonghyun Lee, Jinjoo Kim, and Sangyong Jon. “Self-assembled nanoparticles of a peptide-drug conjugate for targeted cancer therapy.” The 42th Annual Meeting & Exposition of the Controlled Release Society, July 25-29, 2015, Edinburgh, Scoltland, UK. (Poster presentation)

[5] Yonghyun Lee, Sunghyun Kim, Hyungjun Kim, Soyoung Lee, Byung-heon Lee, and Sangyong Jon. “A histone H1-specific aptide as a novel apoptotic imaging probe for monitoring anti-cacner drug responses.” World Molecular Image Congress, September 17-20, 2014, Seoul, Korea. (Poster presentation)

[4] Wooseoung Kim, Yonghyun Lee, Park. H, and Yunjin Jung. “Colonic delivery of celecoxib modulates activities of transcriptional factors in the inflamed colonic tissue; implication in repositioning the selective COX-2 inhibitor to an anti-colitic agent.” American Association of pharmaceutical Scienctists, November 2-6, 2014, Sandiego, USA. (Poster presentation)

[3] Yonghyun Lee, Soyoung Lee, Hyungjun Kim, and Sangyong Jon. “Anti-oxidative bilirubin nanovesicles show potential for use in anti-inflammation therapy.” The 41th Annual Meeting & Exposition of the Controlled Release Society, July 13-16, 2014, Chicago, USA. (Poster presenatation)

[2] Yonghyun Lee, Hyun-Jeong Kim, Young-Mi Kim, and Yunjin Jun. “Synthesis and evaluation of N-succinylaspart-1-yl celecoxib as a colon specific prodrug of celecoxib.” Symposium on Development and research of original new drug, July 4-6, 2012, Shenyang, China. (Oral presenatation)

[1] Yonghyun Lee, Young-Shin Kim, Young-Mi Kim, and Yunjin Jung. “Celecoxib-amino acid conjugates as a colon-specific prodrug of the selective COX-2 inhibitor.” Seventh AFMC International Medicinal Chemistry Congress,August 23-27, 2009, Cairns, Queensland, Australia. (Poster presenatation)